

In the claims:

Following is a complete listing of the claims pending in the application, as amended:

1. (currently amended) An isolated polypeptide which is immunoreactive with an antibody that is itself immunoreactive with human prostatic acid phosphatase (PAP) comprising [a] an amino acid sequence presented as SEQ ID NO: 2, including conservative amino acid substitutions that do not alter the sequence by more than 10% [having at least 90% sequence identity to SEQ ID NO: 2].

Claims 2-22 (cancel)

23. (new) A method of inducing an immune response against human prostatic acid phosphatase (PAP) in a mammalian subject, comprising administering to the subject an immunogenic dosage of a composition comprising a xenogeneic form of PAP from a different mammalian species which is immunoreactive with an antibody that is itself immunoreactive with human PAP, wherein said xenogeneic form of PAP has at least 90% sequence identity to SEQ ID NO: 2.

24. (new) The method of claim 23 wherein the xenogeneic form of PAP is mouse PAP.

25. (new) The method of claim 24 wherein the mouse PAP has the amino acid sequence SEQ ID NO: 2.

26. (new) The method of claim 23 wherein said xenogenic form of PAP is produced in insect cells.